Weston, FL – According to filings with the U.S. Securities and Exchange Commission, Iliad Biotechnologies is raising $42,835,745.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Keith Rubin played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Iliad Biotechnologies
ILiAD Biotechnologies is utilizing its B-Tech vector platform to develop next generation vaccines to eradicate infectious diseases and improve lives. Its lead candidate, BPZE1, which has completed Phase 2 clinical trials, is the most advanced next generation vaccine for the prevention of whooping cough, a serious illness caused by Bordetella pertussis.

To learn more about Iliad Biotechnologies, visit http://www.iliadbio.com/

Contact:
Keith Rubin, Chief Executive Officer
800-603-3525
keith@iliadbio.com

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved